Cover Image
市場調查報告書

全球僵直性脊椎炎市場

Global Ankylosing Spondylitis Market 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 322806
出版日期 內容資訊 英文 102 Pages
訂單完成後即時交付
價格
Back to Top
全球僵直性脊椎炎市場 Global Ankylosing Spondylitis Market 2015-2019
出版日期: 2015年01月07日 內容資訊: 英文 102 Pages
簡介

僵直性脊椎炎是脊椎關節症的亞型,由於脊椎發炎的疼痛造成脊椎的動作和胸部擴大受限制。雖然原因不明,不過,HLA-B27遺傳基因有很大的責任。全球僵直性脊椎炎市場在2014∼2019年預計以5.05%的年複合成長率擴大。

本報告提供全球僵直性脊椎炎市場概要與市場趨勢、未來預測、各種治療藥物的收益趨勢、各地區趨勢,及供應商簡介等彙整資料。

第1章 摘要整理

第2章 簡稱清單

第3章 報告的範圍

第4章 市場調查方法

第5章 簡介

第6章 疾病概要

  • 疾病的理解
  • 僵直性脊椎炎的原因
  • 病理學
  • 流行病學
  • 診斷
  • 治療和管理
  • 經濟負擔

第7章 市場環境

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第8章 各作用機制的市場區隔

  • TNF抑制劑
  • COX抑制劑
  • 其他

第9章 各分子類型的市場區隔

  • 生技藥品
  • 小分子

第10章 各給藥途徑的市場區隔

  • 口服
  • 非口服

第11章 各劑型的市場區隔

  • 固態
  • 液體

第12章 各地區的市場區隔

第13章 購買標準

第14章 市場成長的促進要素

第15章 促進要素與其影響

第16章 市場課題

第17章 促進要素與課題的影響

第18章 市場趨勢

第19章 趨勢與其影響

第20章 供應商環境

  • 競爭模式
  • 供應商分析
  • 其他值得注意的供應商

第21章 產品研發線

第22章 主要供應商分析

  • AbbVie Inc.
  • Amgen
  • Janssen Pharmaceuticals
  • Merck
  • Pfizer

第23章 本系列的其他報告

圖表

目錄
Product Code: IRTNTR5050

About Ankylosing Spondylitis

Ankylosing spondylitis is a subtype of spondylarthropathy. The primary symptoms of the disease are inflammatory spinal pain with subsequent limitation of spine mobility and chest expansion. Ankylosing spondylitis can be diagnosed using clinical signs, radiological signs (sacroiliitis) and the presence of HLA-B27 antigen. According to the NIH and NIAMS, ankylosing spondylitis is a type of arthritis, which affects the joints in the vertebral column severely. It is a progressive inflammatory disease that typically becomes evident during early to mid-adulthood, as per NORD. It can also lead to the loss of spinal mobility for the affected individuals. The cause of the disease is not known, however, the HLA-B27 gene plays a major role. Ankylosing spondylitis is hereditary in nature.

TechNavio's analysts forecast the Global Ankylosing Spondylitis market to grow at a CAGR of 5.05 percent over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Ankylosing Spondylitis market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of ankylosing spondylitis. The market is segmented based on the mechanism of action of the drugs used to treat ankylosing spondylitis as illustrated below:

  • TNF Inhibitors
  • COX Inhibitors
  • Others

On the type of molecule used for the treatment of ankylosing spondylitis, as illustrated below:

  • Biologics
  • Small Molecules

On the basis of route of administration adopted for the treatment of ankylosing spondylitis, the Global Ankylosing Spondylitis market is segmented as follows:

  • Oral
  • Parenteral

In addition, the market is also bifurcated on the basis of dosage forms of the drugs used in the treatment of the disease:

  • Solid
  • Liquid

The report also presents the vendor landscape and a corresponding detailed analysis of the top five vendors in the market. The vendor landscape section includes a market share analysis of the major vendors along with the competitive performances of their product portfolios. In addition, it discusses the major drivers that influence the growth of the market and also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market. Also, the late-stage pipeline molecules developed for the treatment of Ankylosing Spondylitis have been discussed.

TechNavio's report, Global Ankylosing Spondylitis Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, the APAC region and the EMEA; it also covers the Global Ankylosing Spondylitis market landscape and its growth prospects in the coming years. The report also includes a discussion on the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • Abbvie
  • Amgen
  • Janssen Pharmaceuticals
  • Merck & Co.
  • Pfizer

Other Prominent Vendors

  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celgene
  • Celltrion
  • Eisai
  • F. Hoffmann-La Roche
  • Merck Sharp & Dohme
  • Novartis
  • Otsuka Pharmaceutical
  • Regeneron Pharmaceuticals
  • Sanofi
  • Shanghai Pharmaceuticals
  • UCB

Market Driver

  • Presence of Unmet Need
  • For a full, detailed list, view our report

Market Challenge

  • Threat from Patent Expiry
  • For a full, detailed list, view our report

Market Trend

  • Market Dominance by Biologics
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Disease Overview

  • 06.1. Understanding the Disease
  • 06.2. Causes of Ankylosing Spondylitis
  • 06.3. Pathophysiology
  • 06.4. Epidemiology
  • 06.5. Diagnosis
  • 06.6. Treatment and Management
    • 06.6.1. Analgesics
    • 06.6.2. Corticosteroids
    • 06.6.3. DMARDs
    • 06.6.4. Biologics
    • 06.6.5. Physiotherapy
    • 06.6.6. Surgery
  • 06.7. Economic Burden

07. Market Landscape

  • 07.1. Market Overview
  • 07.2. Market Size and Forecast
  • 07.3. Five Forces Analysis

08. Market Segmentation by Mechanism of Action

  • 08.1. TNF Inhibitors
  • 08.2. COX Inhibitors
  • 08.3. Others

09. Market Segmentation by Type of Molecule

  • 09.1. Biologics
  • 09.2. Small Molecules

10. Market Segmentation by Route of Administration

  • 10.1. Oral
  • 10.2. Parenteral

11. Market Segmentation by Dosage Forms

  • 11.1. Solid
  • 11.2. Liquid

12. Geographical Segmentation

13. Buying Criteria

14. Market Growth Drivers

15. Drivers and their Impact

16. Market Challenges

17. Impact of Drivers and Challenges

18. Market Trends

19. Trends and their Impact

20. Vendor Landscape

  • 20.1. Competitive Scenario
    • 20.1.1. Key News
    • 20.1.2. Mergers and Acquisitions
  • 20.2. Market Share Analysis 2014
    • 20.2.1. Competitive Assessment of the Top Drugs for Ankylosing Spondylitis
    • 20.2.2. Abbvie
    • 20.2.3. Janssen Pharmaceuticals
    • 20.2.4. Amgen
    • 20.2.5. Pfizer
    • 20.2.6. Merck
  • 20.3. Other and Future Prominent Vendors

21. Pipeline Portfolio

22. Key Vendor Analysis

  • 22.1. AbbVie Inc.
    • 22.1.1. Key Facts
    • 22.1.2. Business Overview
    • 22.1.3. Product Segmentation by Revenue 2013
    • 22.1.4. Product Segmentation by Revenue 2012 and 2013
    • 22.1.5. Sales by Geography
    • 22.1.6. Business Strategy
    • 22.1.7. Key Developments
    • 22.1.8. SWOT Analysis
  • 22.2. Amgen
    • 22.2.1. Key Facts
    • 22.2.2. Business Overview
    • 22.2.3. Business Segmentation by Revenue 2013
    • 22.2.4. Product Portfolio by Revenue 2013
    • 22.2.5. Business Segmentation by Revenue 2012 and 2013
    • 22.2.6. Geographical Segmentation by Revenue 2013
    • 22.2.7. Business Strategy
    • 22.2.8. Recent Developments
    • 22.2.9. SWOT Analysis
  • 22.3. Janssen Pharmaceuticals
    • 22.3.1. Key Facts
    • 22.3.2. Business Overview
    • 22.3.3. Recent Developments
    • 22.3.4. SWOT Analysis
  • 22.4. Merck
    • 22.4.1. Key Facts
    • 22.4.2. Business Overview
    • 22.4.3. Business Segmentation by Revenue 2013
    • 22.4.4. Business Segmentation by Revenue 2012 and 2013
    • 22.4.5. Sales by Geography
    • 22.4.6. Business Strategy
    • 22.4.7. Key Developments
    • 22.4.8. SWOT Analysis
  • 22.5. Pfizer
    • 22.5.1. Key Facts
    • 22.5.2. Business Overview
    • 22.5.3. Business Segmentation by Revenue 2013
    • 22.5.4. Business Segmentation by Revenue 2012 and 2013
    • 22.5.5. Geographical Segmentation by Revenue
    • 22.5.6. Business Strategy
    • 22.5.7. Key Developments
    • 22.5.8. SWOT Analysis

23. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Executive Summary of Global Ankylosing Spondylitis Market 2014-2019
  • Exhibit 3: Snapshot of Ankylosing Spondylitis
  • Exhibit 4: Diagnosis of Ankylosing Spondylitis
  • Exhibit 5: Treatment and Management of Ankylosing Spondylitis
  • Exhibit 6: Snapshot of the Economic Burden of Ankylosing Spondylitis
  • Exhibit 7: Snapshot of the Global Ankylosing Spondylitis Market
  • Exhibit 8: Global Ankylosing Spondylitis Market 2014-2019 (US$ million)
  • Exhibit 9: Drivers and Challenges of Global Ankylosing Spondylitis Market
  • Exhibit 10: Global Ankylosing Spondylitis Market Segmentation by Mechanism of Action
  • Exhibit 11: Global Ankylosing Spondylitis Market Segmentation by Mechanism of Action 2014
  • Exhibit 12: Global Ankylosing Spondylitis Market Segmentation by Type of Molecule
  • Exhibit 13: Global Ankylosing Spondylitis Market Segmentation by Type of Molecule 2014
  • Exhibit 14: Global Ankylosing Spondylitis Market Segmentation by Route of Administration
  • Exhibit 15: Global Ankylosing Spondylitis Market Segmentation by Route of Administration 2014
  • Exhibit 16: Global Ankylosing Spondylitis Market Segmentation by Dosage Forms
  • Exhibit 17: Global Ankylosing Spondylitis Market Segmentation by Dosage Forms 2014
  • Exhibit 18: Global Ankylosing Spondylitis Market by Geographical Segmentation 2014
  • Exhibit 19: Buying Criteria of the Global Ankylosing Spondylitis Market
  • Exhibit 20: Drivers and their Impact on the Key Customer Category of the Global Ankylosing Spondylitis Market
  • Exhibit 21: Drivers and Their Geography-wise Impact on the Global Ankylosing Spondylitis Market
  • Exhibit 22: YoY Sales Comparison of Top Drugs used for Ankylosing Spondylitis 2010-2013 (US$ million)
  • Exhibit 23: Revenue Share of the Top Drugs used for Ankylosing Spondylitis 2010-2013
  • Exhibit 24: Abbvie: Product Portfolio for Ankylosing Spondylitis
  • Exhibit 25: YoY Global Sales of Humira 2008-2013 (US$ million)
  • Exhibit 26: Janssen: Product Portfolio for Ankylosing Spondylitis
  • Exhibit 27: YoY Sales of Remicade 2005-2013 (US$ million)
  • Exhibit 28: YoY Sales of Simponi 2010-2013 (US$ million)
  • Exhibit 29: Amgen: Product Portfolio for Ankylosing Spondylitis
  • Exhibit 30: YoY Sales of Enbrel (In US and Canada) 2005-2013 (US$ million)
  • Exhibit 31: YoY Sales of Enbrel In US 2005-2013 (US$ million)
  • Exhibit 32: YoY Sales of Enbrel In Canada 2005-2013 (US$ million)
  • Exhibit 33: Region-wise Sales Comparison of Enbrel 2005-2013 (US$ million)
  • Exhibit 34: Pfizer: Product Portfolio for Ankylosing Spondylitis
  • Exhibit 35: YoY Sales of Enbrel (Outside US and Canada) 2009-2013 (US$ million)
  • Exhibit 36: YoY Sales of Enbrel (Outside US and Canada) 2008-2013 (US$ million)
  • Exhibit 37: Merck: Product Portfolio for Ankylosing Spondylitis
  • Exhibit 38: YoY Sales of Remicade 2005-2013 (US$ million)
  • Exhibit 39: YoY Sales of Simponi 2010-2013 (US$ million)
  • Exhibit 40: AbbVie Inc.: Product Segmentation by Revenue 2013
  • Exhibit 41: AbbVie Inc.: Product Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 42: AbbVie Inc.: Sales by Geography 2013
  • Exhibit 43: Amgen: Business Segmentation by Revenue 2013
  • Exhibit 44: Amgen: Product Portfolio by Revenue 2013
  • Exhibit 45: Amgen: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 46: Amgen: Geographical Segmentation by Revenue 2013
  • Exhibit 47: Merck & Co. Inc.: Business Segmentation by Revenue 2013
  • Exhibit 48: Merck & Co. Inc.: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 49: Merck & Co. Inc.: Sales by Geography 2013
  • Exhibit 50: Pfizer: Business Segmentation by Revenue 2013
  • Exhibit 51: Pfizer: Business Segmentation by Revenue 2012 and 2013
  • Exhibit 52: Pfizer: Geographical Segmentation by Revenue 2013
Back to Top